Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
To compare the efficacy and safety of PERT-IJS (Proposed biosimilar Pertuzumab) plus trastuzumab and chemotherapy (carboplatin and docetaxel) versus EU-Perjeta plus trastuzumab and chemotherapy (carboplatin and docetaxel) in neoadjuvant treatment of patients with HR-ve and HER-2 positive early stage or locally advanced breast cancer.
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
BIOLOGICAL: PERT-IJS plus trastuzumab, carboplatin and docetaxel|BIOLOGICAL: Perjeta plus trastuzumab, carboplatin and docetaxel
Efficacy endpoint - Total pathologic complete response between Treatment arm A and Treatment Arm B, Total pathologic complete response (tpCR; ypT0/Tis,ypN0) in breast and axillary nodes after neoadjuvant treatment by Independent Review Committee (IRC), Week 18
Efficacy endpoint-Total pathologic complete response between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen, Total pathologic complete response (tpCR; ypT0/Tis, ypN0) in breast and axillary nodes after neoadjuvant treatment by local histopathologist, Week 18|Efficacy endpoint: Pathologic complete response between Treatment Arm A and Treatment Arm B, Pathologic complete response (pCR; ypT0/ypN0) after neoadjuvant treatment by IRC and local histopathologist, Week 18|Efficacy endpoint- Breast pathologic complete response between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen, Breast pathologic complete response (bpCR; ypT0/Tis) after neoadjuvant treatment by IRC and local histopathologist, Week 18|Efficacy endpoint-Objective response rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen, Objective response rate (ORR) after neoadjuvant treatment in accordance with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Week 18|Efficacy endpoint-Event free survival rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen, Event free survival (EFS) rate, Week 18|Efficacy endpoint- Overall survival rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen, Overall survival (OS) rate, Week 18|Efficacy endpoint-EFS rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout, EFS rate, 1 Year|Efficacy endpoint - Overall Survival rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout, Overall survival rate, 1 Year|Efficacy endpoint - Overall Response Rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout, Overall Response Rate, 1 Year|Efficacy Endpoint: EFS rate after the single switch from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on Treatment B, EFS rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab, 1 year|Efficacy Endpoint: Disease free survival rate after the single switch from from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on EU-Perjeta+trastuzumab, Disease free survival (DFS) rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab, 1 year|Efficacy Endpoint: Overall survival rate after the single switch from from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on EU-Perjeta+trastuzumab, OS rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab, 1 year|Pharmacokinetic (PK) endpoint-The trough serum concentration, The trough serum concentration (Ctrough), 1 Year|Safety Endpoint: treatment-emergent adverse events and serious adverse events, Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), week 18|Safety Endpoint: left ventricular ejection fraction, Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%, week 18|Safety Endpoint: Vital signs, Number of subjects with clinically significant changes in Vital signs, week 18|Safety Endpoint-ECG PR Interval, Number of subjects with clinically significant changes in ECG PR Interval, week 18|Safety Endpoint-ECG QRS Interval, Number of subjects with clinically significant changes in ECG QRS Interval, week 18|Safety Endpoint-ECG QT Interval, Number of subjects with clinically significant changes in ECG QT Interval, week 18|Safety Endpoint- ECG corrected QT interval (QTc) Interval, Number of subjects with clinically significant changes in ECG QTc Interval, week 18|Safety Endpoint-clinical laboratory assessments, Number of subjects with clinically significant changes in Clinical laboratory assessments, week 18|Safety Endpoint-pregnancy test, Number of subjects with Pregnancy outcome, week 18|Safety Endpoint-physical examination, Number of subjects with clinically significant changes in Physical examination, week 18|Immunogenicity Endpoint, Immunogenicity (anti-drug antibodies (ADA) and neutralizing antibodies (nAb) titers), week 18|Safety Endpoint: treatment-emergent adverse events and serious adverse events of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta, Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), 1 year|Safety Endpoint: left ventricular ejection fraction of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout, Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS -throughout compared to patients randomized to EU-Perjeta throughout- Vital signs, Number of subjects with clinically significant changes in Vital signs, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- ECG PR Interval, Number of subjects with clinically significant changes in ECG PR Interval, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-ECG QRS Interval, Number of subjects with clinically significant changes in ECG QRS Interval, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-ECG QT Interval, Number of subjects with clinically significant changes in ECG QT Interval, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- ECG QTc Interval, Number of subjects with clinically significant changes in ECG QTc Interval, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-Clinical laboratory assessments, Number of subjects with clinically significant changes in Clinical laboratory assessments, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- Pregnancy test, Number of subjects with Pregnancy outcome, 1 year|Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-Physical examination, Number of subjects with clinically significant changes in Physical examination, 1 year|Immunogenicity Endpoint of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout, Immunogenicity (anti-drug antibodies (ADA) and neutralizing antibodies (nAb) titers), 1 year|Safety Endpoint: Incidence of TEAEs and SAEs after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab throughout, Incidence of TEAEs and SAEs after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab, 1 Year|Safety End Point :left ventricular ejection fraction incidences after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab, Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%, 1 year|Immunogenicity End Point: after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab, Immunogenicity (ADA titer and nAb titer) after switching of treatment from EU-Perjeta to PERT-IJS plus trastuzumab versus those continuing on EU-Perjeta + trastuzumab, 1 Year
This study is designed to compare the efficacy and safety of proposed biosimilar PERT-IJS plus trastuzumab, carboplatin and docetaxel versus EU-Perjeta plus trastuzumab, carboplatin and docetaxel in neoadjuvant treatment of HR-ve HER2-positive Early Breast Cancer (EBC) (invasive breast cancer without distant metastasis) or locally advanced breast cancer patients.